Found: 3
Select item for more details and to access through your institution.
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study.
- Published in:
- Allergy, 2022, v. 77, n. 7, p. 2175, doi. 10.1111/all.15175
- By:
- Publication type:
- Article
Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.
- Published in:
- Pediatric Allergy & Immunology, 2023, v. 34, n. 7, p. 1, doi. 10.1111/pai.13982
- By:
- Publication type:
- Article
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.
- Published in:
- Pharmaceutics, 2023, v. 15, n. 9, p. 2266, doi. 10.3390/pharmaceutics15092266
- By:
- Publication type:
- Article